演題詳細

ポスター / Poster

ポスター 36 (Poster 36) :骨髄腫:その他

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
池田 宇次 (Takashi Ikeda):1
1:静岡県立静岡がんセンター 血液・幹細胞移植科
 
前へ戻る

Prognostic studies of previously untreated symptomatic multiple myeloma: An empirical appraisal

演題番号 : PS-1-270

寺澤 晃彦 (Teruhiko Terasawa):1,2,6、Nikolaos Trikalinos:3、小島 勇貴 (Yuki Kojima):2、Issa Dahabreh:5、永井 宏和 (Hirokazu Nagai):2、Benjamin Djulbegovic:4

1:Dept. Gen. Int. Med., Fujita Health Univ., Toyoake, Japan、2:Clin. Res. Center Blood Dis., Nagoya Med. Center, Nagoya, Japan、3:Univ. Maryland, Marlene Stewart Greenebaum Cancer Center, Baltimore, USA、4:Center Evid. Base. Med. Health Outcome Res., Univ. South Florida, Tampa, USA、5:Center Evid. Base. Med. Brown Univ., Providence, USA、6:Inst. Clin. Res. Health Policy Studies., Tufts Univ., Boston, USA

 

Objective: Studies have assessed several biomarkers to predict treatment outcomes of patients with multiple myeloma (MM). We performed an empirical assessment of the currently reported literature. Materials and methods: We searched PubMed (from 1996 through June, 2012) to identify studies of treatment outcomes in previously untreated symptomatic MM. We analyzed overall survival (OS) or similar entities using test results as a predictor of treatment outcomes. We extracted study characteristics, assessed markers and/or models, analysis methods, and presentation, and performed qualitative syntheses. We herein report the results from studies published between 2008 and 2012. Results: A total of 185 studies were evaluated. Very few studies (n=2, 1%) explicitly planned before analysis how they selected particular markers. Most studies had a retrospective design (n=172, 93%) with inconsecutive enrollment (n=147, 79%). The median sample size was 200, and the median followup period was 40 months. OS was the most commonly assessed outcome (n=169, 91%). Of 178 studies (96%) that reported at least one single prognostic marker, about half also assessed multiple tests jointly as a prognostic model. Only 64 studies (35%) assessed International Staging System. Although most studies (n=169, 91%) reported statistically significant results, few validated the results in the same report (internal validation (n=6); external validation (n=15)). Only 26 studies (14%) analyzed the data based on an inception cohort. Conclusion: Few studies used rigorous research methods to evaluate prognostic models.

前へ戻る